Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 22,252 results that match your search.22,252 results
  • Petitions accepted, but only on some claims Litigation usually stayed Oblon Spivak handles most cases As of February 22, there have been 142 petitions for inter-partes review (IPR) and 15 petitions for post-grant review of covered business methods (CBM) filed at the USPTO – but how are they being decided? And what effect have they had on litigation?
  • Seen as benefiting foreign companies Lack of trade mark oppositions Slow take-up in Colombia too The Madrid Protocol came into force in Mexico in February, but the government's failure to introduce a trade mark opposition system has created problems, especially for domestic companies.
  • Natco licence confirmed Government report says prices too high Three cancer drugs up next It keeps getting worse for patent owners in India. Last month the IP Appellate Board upheld the compulsory licence issued to Natco over a Bayer drug, Nexavar, and then a government report recommended more.
  • It is a little strange that, with all the focus on the IP activity of Chinese companies in recent years, no one has yet collected all the relevant information about them in one place. That's what two of our staff – group editor Emma Barraclough and Asia reporter Peter Leung – began doing a few months ago, and the first fruits are laid out from page 30.
  • This list of PCC cases, the parties and rulings, runs from the first cases under the new procedural rules to March 2013.
  • As I have mentioned in prior postings, one of my tasks this year as AIPLA President is to represent U.S. intellectual property interests around the world. (By the way, I learned that people in some South American countries pronounce our country’s U.S.A. initials as a word, such as asking “Are you from Ooh-SAh?”) There are a number of issues that keep coming up in discussion, but the one I’d like to focus on today is “patent attorneys” and privilege.
  • Today’s blog looks at AstraZeneca’s Crestor settlement and today’s Supreme Court hearing on reverse payments, the harmonisation of Google’s AdWords policy and a patent on twitter. We also cast a critical eye over the latest EU Action Plan
  • Ugur Aktekin, Özge Atilgan Karakulak and Hande Hançer of Mehmet Gün & Partners counter the perception that Turkey’s enforcement tools are inefficient, and detail the best ways to tackle infringement
  • Emre Kerim Yardimci of Deris Patents and Trademarks Agency explains the proposed amendments to patent legislation in Turkey, where investment and filings are increasing year on year
  • The head of IP at one of Turkey’s biggest manufacturers explains to Simon Crompton how the company became an innovator and the challenges of protecting its IP in Europe